ArticleCancer imaging : the official publication of the International Cancer Imaging Society2025
CD31-associated vascular phenotyping using Doppler ultrasound and dual-energy CT for recurrence risk stratification in papillary thyroid cancer.
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAngiogenesis plays a pivotal role in PTC aggressiveness and recurrence. CD31, an endothelial marker, provides a histological correlate of tumor vascularity. This study aimed to establish a multimodal imaging framework using Doppler ultrasound (US) and dual-energy CT (DECT) to capture CD31-associated vascular phenotypes for recurrence risk stratification.
methodsA total of 414 PTC patients (training set, 151; test set 1, 137; test set 2, 126) were included. Clinical and radiographic features, including demographics, tumor morphology, Doppler US grade, US grayscale values, and DECT parameters, were analyzed. CD31 expression was assessed by immunohistochemistry in the training set and served as a reference for vascular phenotyping. Logistic regression was applied to identify imaging-derived vascular signatures linked to CD31 expression. Recurrence-free survival (RFS) was analyzed across all datasets to evaluate prognostic value.
resultsHigh CD31 expression correlated with advanced tumor stage (p = 0.003), lymph node metastasis (p = 0.001), extrathyroidal extension (p < 0.001), and recurrence (p < 0.001). The vascular phenotype model integrating Doppler US grade, unenhanced electron density (ED), arterial-phase iodine concentration (IC), and venous-phase IC/ED ratio achieved an AUC of 0.815 (95% CI: 0.744–0.874) for discriminating CD31 expression in the training set. This imaging-derived phenotype was significantly associated with RFS in the training set (p = 0.017), test set 1 (p = 0.006), and test set 2 (p = 0.002), effectively identifying patients at higher risk of recurrence.
conclusionPreoperative vascular phenotyping with Doppler US and DECT enables noninvasive assessment of CD31-associated angiogenic activity and enhances recurrence risk stratification in PTC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.